Congressional efforts to restrict access to the medication mifepristone have intensified following the introduction of new legislation aimed at banning the drug and removing its federal approval. On Wednesday, March 11, 2026, U.S. Senator Josh Hawley (R-Mo.) unveiled a legislative push that centers on mifepristone safety and congressional action, arguing that the medication poses inherent risks to women and is subject to abuse.
The proposed legislation, known as the Safeguarding Women from Chemical Abortion Act, seeks to ban the use of mifepristone for abortions and provides a legal pathway for women who claim to have been harmed by the drug to sue its manufacturers. Senator Hawley hosted a press conference to introduce the bill, which featured testimonies from women who reported being harmed by the medication and statements from pro-life leaders calling for the drug’s removal from the market.
Joining the effort in the House of Representatives is Congresswoman Diana Harshbarger (TN-01), who is introducing companion legislation. Harshbarger, a pharmacist, has emphasized the need for strict medical oversight and transparency, alleging that the Food and Drug Administration (FDA) has eroded safety safeguards under previous administrations.
The Safeguarding Women from Chemical Abortion Act
Senator Hawley’s legislative strategy focuses on both the availability of the drug and the accountability of the companies that produce it. During the March 11 announcement, Hawley stated, “The science is clear: the chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it.” Senator Hawley’s office confirmed the bill’s intent to protect women’s health by banning mifepristone and empowering legal action against manufacturers.
The push to remove FDA approval for mifepristone’s use in ending pregnancies is part of a broader effort to shift how the drug is regulated and accessed within the United States. According to reports from The Hill, the legislation has gained rapid traction among certain congressional members seeking to overturn existing FDA authorizations.
Challenges to FDA Oversight and REMS Modifications
A central point of contention in the current congressional debate involves the Risk Evaluation and Mitigation Strategy (REMS), a safety program designed by the FDA to ensure that the benefits of a drug outweigh its risks. Specifically, legislators are targeting modifications made by the FDA in January 2023.
Congresswoman Diana Harshbarger has argued that these modifications dismantled critical safety protocols. According to Harshbarger, the FDA’s actions included:
- The removal of requirements for in-person dispensing of the medication.
- Allowing the drug to be shipped through the mail.
- Limiting the reporting of adverse events, which Harshbarger claims prevents the tracking of serious complications.
These concerns are mirrored in the 119th Congress through H.R.679, a bill specifically designed to nullify the January 2023 FDA modifications to the mifepristone REMS. The legislation aims to restore previous restrictions on how the drug is distributed and monitored.
Impact on Healthcare Policy and Patient Access
The debate over mifepristone safety and congressional action reflects a significant divide in the interpretation of federal drug policy. Whereas the FDA previously expanded access to the drug to increase patient convenience and availability, current legislative efforts seek to revert these changes based on the belief that real-world risks are higher than the federal government has acknowledged.
For healthcare providers and patients, the potential passage of the Safeguarding Women from Chemical Abortion Act or H.R.679 would represent a fundamental shift in reproductive healthcare delivery. The restoration of in-person dispensing requirements and the potential ban on the drug would eliminate mail-order options and restrict the legal use of the medication for ending pregnancies.
Summary of Current Legislative Actions
| Legislation | Primary Objective | Key Proponent |
|---|---|---|
| Safeguarding Women from Chemical Abortion Act | Ban mifepristone. allow lawsuits against manufacturers | Sen. Josh Hawley / Rep. Diana Harshbarger |
| H.R.679 | Nullify January 2023 FDA REMS modifications | 119th Congress |
As these bills move through the legislative process, the focus remains on whether the FDA’s current safety protocols are sufficient or if congressional intervention is required to restore stricter oversight. The outcome of these actions will likely depend on the balance of power within the 119th Congress and the legal challenges that typically follow changes to FDA-approved drug protocols.
The next confirmed checkpoint for these measures will be the progress of H.R.679 and the companion legislation in the House and Senate committees. We will continue to monitor official congressional filings and FDA updates as they turn into available.
Do you have thoughts on how healthcare policy should balance patient access with regulatory oversight? Share your perspective in the comments below.